Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003

Urology

Volumn 62, Issue 6 SUPPL. 1, 2003, Pages 20-28

  Moul, Judd W ^a   Fowler Jr , Jackson E ^b  

^a Center for Prostate Disease Research   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ERECTILE DYSFUNCTION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; LIBIDO DISORDER; META ANALYSIS; METASTASIS; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0346368078     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.10.014     Document Type: Article

References (36)

1. Moul J.W., Wu H., Sun L., et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen an overview of the Department of Defense Center for Prostate Disease Research national database . Surgery. 132:2002;213-219.
2. National Cancer Institute. Prostate cancer. Available at: http://www.seer.cancer.gov. Accessed May 6, 2003.
3. Byar DP: The Veterans Administration Cooperative Urological Research Group studies of cancer of the prostate. Cancer 32: 1126-1130, 1973.
4. Byar DP, and Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. J Natl Cancer Inst Monogr 7: 165-170, 1988.
5. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 79: 235-246, 1997.
6. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenopathy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
7. Messing E, Manola J, Sarosdy, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 169: 396, 2003. Abstract 1480.
8. Walsh P.C., DeWeese T.L., Eisenberger M.A. A structured debate immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment . J Urol. 166:2001;508-515.
9. Schroeder F.H., Kurth K.H., Fossa S.D., et al. Early versus delayed endocrine treatment in PN1-3 M0 prostate cancer without local treatment of the primary tumor. J Urol. 169:2003;396. Abstract 1487.
10. Walsh P.C., DeWeese T.L., Eisenberger M.A. A structured debate immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment . J Urol. 166:2001;508-515. Discussion 515-516.
11. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
12. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) a phase III randomised trial . Lancet. 360:2002;103-108.
13. Moul J.W. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Mol Urol. 4:2000;267-271.
14. Sun L., Moul J.W., Wu H., et al. Natural history of prostate cancer in 3605 CPDR patients receiving radical prostatectomy and factors affecting post-treatment clinical metastasis in PSA era. J Urol. 169:2003;398. Abstract 1489.
15. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
16. Cadeddu J.A., Partin A.W., DeWeese T.L., et al. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 159:1998;173-177.
17. Hinkle G.H., Burgers J.K., Neal C.E., et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 83:1998;739-747.
18. Moul J.W., Sun L., McLeod D.G., et al. Retrospective review on 542 cases in the past decade on associations between bone metastasis and PSA level, bone, and race in prostate cancer patients. Oncology. 17:2003;47. abstract.
19. Moul J.W., Connelly R.R., Lubeck D.P., et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 166:2001;1322-1327.
20. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with or without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
21. Denis L.J., Keuppens F., Smith P.H., et al. Maximal androgen blockade final analysis of EORTC phase III trial 30853 . Eur Urol. 33:1998;144-151.
22. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 339:1998;1036-1042.
23. Bono A.V., DiSilverio F., Robustelli della Cuna G. Complete androgen blockade versus chemical castration in advanced prostatic cancer analysis of an Italian multicentre study . Urol Int. 60:(suppl 1):1998;18-24.
24. Boccardo F., Pace M., Rubagotti A., et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostatic cancer. Eur J Cancer. 29A:1993;1088-1093.
25. Thorpe S.C., Azmatullah S., Fellows G.J., et al. A prospective randomized study to compare goserelin acetate versus cyproterone acetate versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol. 29:1996;47-54.
26. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355: 1491-1498, 2000.
27. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer a preliminary report . Urology. 45:1995;839-844.
28. Gleave M., Bruchovsky N., Goldenberg S.L., et al. Intermittent androgen suppression for prostate cancer rationale and clinical experience . Eur Urol. 34:1998;37-41.
29. Akakura K., Bruchovsky N., Goldenberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors apoptosis and serum prostate-specific antigen . Cancer. 71:1993;2782-2790.
30. Prapotnich D., Fizazi K., Escudier B., et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol. 43:2003;233-240.
31. De La Taille A., Zerbib M., Conquy S., et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int. 91:2003;18-22.
32. Powell IJ, Tangen CM, Miller GJ, et al: Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, phase II Southwest Oncology Group Study 9109. J Urol 168: 2016-2019, 2002.
33. Lawton CA, Winter K, Murray K, et al: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49: 937-946, 2001.
34. Pilepich MV, Winter K, John MJ, et al: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243-1252, 2001.
35. Hanks GE, Lu J, Machtay M, et al: RTOG protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy for locally advanced carcinoma of the prostate: proceedings of American Society of Clinical Oncology 2000. J Clin Oncol 19: 327a, 2000. Abstract 1284.
36. Shipley WU, Lu JD, Pilepich MV, et al: Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54: 1302-1310, 2002.